EUVIMEDEUVIMED entdecken
Crossref

Prognostic value of [64Cu]GD2 PET beyond [18F]FDG PET in sarcoma patients

N Trautwein, H Dittmann, S Kailayangiri, CK W. Deinzer, G Reischl, P Lang, C Blattmann, J Schäfer, B Pichler, C Rössig, C la Fougère, J Schwenck

Nuklearmedizin - NuclearMedicine · 01.04.2026 · 65 (02) · 126-127

DOI: 10.1055/s-0046-1818240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2026. Verfasst von N Trautwein und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ziel/Aim: Despite their rarity, osteosarcoma, rhabdomyosarcoma, and Ewing’s sarcoma are causing approximately 10% of cancer-related deaths in children. GD2, a tumor-associated surface antigen, is variably expressed in sarcomas, yet its biological role and prognostic significance remain unclear. GD2-targeted antibody and CART-cell therapies have been developed and are under clinical investigation mainly in neuroblastoma patients. Here, we employed [ 64 Cu]GD2 whole body PET to non-invasively assess GD2 expression patterns in tumors and metastases, providing new insights into the role of GD2 in sarcomas. Methodik/Methods: We retrospectively analyzed 20 patients with histologically confirmed sarcoma who underwent [ 64 Cu]GD2 PET. Tumor uptake was quantified using SUVmean/SUVmax derived by a 50% threshold method. Patients were classified as GD2 positive (GD2+) if≥50% of their lesions showed an uptake equal to or greater than the blood pool. In 16 patients, additional [ 18 F]FDG PET scans were available for comparison. Tumor tissue samples were available in 13 patients and analyzed for GD2 expression by immunofluorescence (IF) staining as previously described [ 1 ]. Ergebnisse/Results: 8/20 patients were classified as GD2+according to [ 64 Cu]GD2 PET. Per definition GD2+patients showed significantly higher [ 64 Cu]GD2 uptake (7.7±3.6 vs 4.1±2.2) than GD2- patients. SUVmean correlated strongly and significantly with the IF GD2 expression score ex vivo ( r =0.7, p

Zitieren

APA

Trautwein, N., Dittmann, H., Kailayangiri, S., Deinzer, C. W., Reischl, G., Lang, P., Blattmann, C., Schäfer, J., Pichler, B., Rössig, C., Fougère, C. L., & Schwenck, J. (2026). Prognostic value of [64Cu]GD2 PET beyond [18F]FDG PET in sarcoma patients. Nuklearmedizin - NuclearMedicine, 65(02), 126-127. https://doi.org/10.1055/s-0046-1818240

Vancouver

Trautwein N, Dittmann H, Kailayangiri S, Deinzer CW, Reischl G, Lang P, et al. Prognostic value of [64Cu]GD2 PET beyond [18F]FDG PET in sarcoma patients. Nuklearmedizin - NuclearMedicine. 2026;65(02):126-127. doi:10.1055/s-0046-1818240

BibTeX
@article{Trautwein2026,
  author = {Trautwein, N and Dittmann, H and Kailayangiri, S and Deinzer, CK W. and Reischl, G and Lang, P and Blattmann, C and Schäfer, J and Pichler, B and Rössig, C and Fougère, C la and Schwenck, J},
  title = {Prognostic value of [64Cu]GD2 PET beyond [18F]FDG PET in sarcoma patients},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2026},
  volume = {65},
  number = {02},
  pages = {126--127},
  doi = {10.1055/s-0046-1818240}
}
Kostenlos starten →